Azithromycin for cystic fibrosis

Southern K.W., Barker P.M.

Source: Eur Respir J 2004; 24 : 834-838
Journal Issue: November

Congress or journal article abstractPDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Southern K.W., Barker P.M.. Azithromycin for cystic fibrosis. Eur Respir J 2004; 24 : 834-838

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018



Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020


Resistive inspiratory manoeuvre as airway clearance technique in stable patients with cystic fibrosis: A randomised crossover trial
Source: International Congress 2016 – Physiotherapy management of the ill but spontaneously-breathing adult patient
Year: 2016


Hypertonic saline nebulization combined with oscillatory positive expiratory pressure accelerate sputum clearance in cystic fibrosis: A randomised crossover trial
Source: International Congress 2016 – Physiotherapy management of the ill but spontaneously-breathing adult patient
Year: 2016


Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: a randomised crossover trial
Source: Eur Respir J, 53 (4) 1801793; 10.1183/13993003.01793-2018
Year: 2019



Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial
Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2017




A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis
Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Year: 2009


Bubble-positive expiratory pressure improves sputum clearance in people with bronchiectasis: a randomised crossover trial
Source: International Congress 2017 – Airway clearance techniques and respiratory physiotherapy in hospitalized patients
Year: 2017


Exercise training is beneficial in patients with non-cystic fibrosis bronchiectasis – A multi-centre, randomised controlled trial
Source: Annual Congress 2012 - Exercise and physical activity: towards evidence-based benefits in different populations
Year: 2012


RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017
Year: 2018



RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017
Year: 2018



A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2009; 34: 1086-1092
Year: 2009



What is new in paediatric cystic fibrosis?
Source: Annual Congress 2006 - Paediatric year in review
Year: 2006


Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study
Source: ERJ Open Res, 3 (4) 00100-2017; 10.1183/23120541.00100-2017
Year: 2017



Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013


Azithromycin for early pseudomonas infection in cystic fibrosis: the OPTIMIZE randomised trial
Source: International Congress 2019 – Therapeutic breakthrough Year in review
Year: 2019


Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Source: Eur Respir Rev 2008; 17: 116-122
Year: 2008



LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013



Heliox and alveolar oxygenation in patients with chronic obstructive pulmonary disease: a multicentre, randomised, crossover study
Source: Eur Respir J 2004; 24: Suppl. 48, 243s
Year: 2004